BioLife Solutions, Inc. (BLFS) Stock Analysis
Healthcare · Medical Instruments & Supplies · NasdaqCM
BioLife Solutions, Inc. (BLFS) posted $96.21M in revenue for fiscal 2025 (up 17.0% year over year), with a net loss of $4.59M, and has compounded revenue about 14.9%/yr over five years, per its SEC filings.
Data last refreshed August 2, 2026 from SEC filings · how we compute this
The analyst's take on BioLife Solutions, Inc.
BioLife Solutions, Inc. has grown revenue from $0 to $96.21M over the last 10 fiscal years, compounding about 14.9% a year. The most recent year was up 17%, so growth is actually accelerating.
Net margin sits at -4.8%, up 19.7 points year over year on a 64.6% gross margin. It carries about $5.00M of total debt.
At today's valuation the market is pricing in roughly 32.9% annual free-cash-flow growth — versus the 17.8% it actually delivered over the last five years, so the price already assumes a step-up from the recent record. The one thing worth a second look in the filings is share count rising (dilution).
Synthesised from BioLife Solutions, Inc.'s SEC filings — descriptive, not advice. Ask the analyst your own question →
BioLife Solutions, Inc. revenue & earnings — last 10 fiscal years
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $11.02M | $19.74M | $27.37M | $48.09M | $119.16M | $161.76M | $143.27M | $82.25M | $96.21M |
| Gross profit | $4.78M | $6.75M | $13.53M | $18.61M | — | — | — | $41.32M | $50.10M | $62.12M |
| Net income | $-6.88M | $-2.52M | $-25.00M | $-1.66M | $1.98M | $-8.91M | $-139.81M | $-66.43M | $-20.18M | $-4.59M |
| Net margin | — | -22.8% | -126.7% | -6.1% | 4.1% | -7.5% | -86.4% | -46.4% | -24.5% | -4.8% |
Source: BioLife Solutions, Inc. SEC filings (10-K). 16 years of history available in the interactive view.
BioLife Solutions, Inc.: 2 potential red flags in the filings
Patterns in the filed statements worth a second look — computed and cited, not AI guesswork, and not a signal to sell. The kind of thing that hides in a 10-K.
- Share count rising (dilution)Shares outstanding grew 15.3% over 4 years (41.8M → 48.2M) — existing holders' stakes are being diluted.
- Currently unprofitableThe latest fiscal year was a net loss (net margin -4.8%).
What growth is priced into BLFS stock?
At today's market cap of $1.31B, BioLife Solutions, Inc. is priced for free-cash-flow growth of about 32.9% per year for 10 years (assuming a 10% discount rate and 2.5% terminal growth, base FCF $10.64M from the FY ending 2025-12-31). For comparison, free cash flow actually grew 17.8%/yr over the last five fiscal years and revenue 14.9%/yr, computed from its SEC filings. This is a reverse DCF — a translation of the price into a growth assumption you can judge, not a fair value and not advice. Change the assumptions yourself in the interactive view →
Explore 16 years of BioLife Solutions, Inc. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track BLFS in your portfolio →
BioLife Solutions, Inc. financial history by metric
Compare BioLife Solutions, Inc. with peers
About BioLife Solutions, Inc.
BioLife Solutions, Inc. develops, manufactures, and markets bioproduction products and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor Freeze Media that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; bioproduction products, such as human platelet lysates for cell expansion and CellSeal closed system vials that are used in CGT; CryoCase cryo-compatible transparent rigid containers for closed-system fill and retrieval, and automated cell processing machines; and the ThawSTAR line include automated thawing devices for frozen cell and gene therapies packaged in cryovials and cryobags. The company also provides evo shipping containers that are cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals. It markets and sells its products directly, as well as through third party distributors. The company was incorporated in 1987 and is headquartered in Bothell, Washington.
BioLife Solutions, Inc. — frequently asked questions
What is BioLife Solutions, Inc.'s revenue?
BioLife Solutions, Inc. (BLFS) reported revenue of $96.21M for fiscal year 2025, up 17.0% from the prior year, according to its SEC filings.
Is BioLife Solutions, Inc. profitable?
No — BLFS reported a net loss of $-4.59M in fiscal 2025.
What is BLFS's P/E ratio?
BioLife Solutions, Inc. trades at a price-to-earnings ratio of about 0.0 based on the latest data in our nightly-refreshed cache.
How fast is BioLife Solutions, Inc. growing?
BLFS's revenue grew at roughly 14.9% per year over the last five fiscal years (compound annual growth rate), computed from SEC-filed statements.
How much debt does BioLife Solutions, Inc. have?
As of fiscal year 2025, BLFS carried roughly $5.00M in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is BioLife Solutions, Inc.'s gross margin?
BLFS's gross margin was 64.6% in fiscal 2025 — gross profit of $62.12M on revenue of $96.21M.
What is BioLife Solutions, Inc.'s market cap?
BioLife Solutions, Inc. (BLFS) has a market capitalization of about $1.31B, based on the latest data in our nightly-refreshed cache.
When does BioLife Solutions, Inc.'s fiscal year end?
BLFS's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
What growth is priced into BLFS stock?
At today's market cap of $1.31B, BioLife Solutions, Inc. is priced for free-cash-flow growth of about 32.9% per year for 10 years (assuming a 10% discount rate and 2.5% terminal growth, base FCF $10.64M from the FY ending 2025-12-31). For comparison, free cash flow actually grew 17.8%/yr over the last five fiscal years and revenue 14.9%/yr, computed from its SEC filings.
Where does this data come from?
All figures are computed from BioLife Solutions, Inc.'s official SEC filings (10-K and 10-Q), covering 16 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.